HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC

This study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…

This study looks at whether adding the drug pembrolizumab to targeted radiation therapy can help people whose head and neck cancer has come back or who have a new tumor in the same area. About 86 adults who cannot have surgery will be randomly assigned to get radiation alone or r…

This early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …

This study tests whether adding an experimental drug (INBRX-106) to a standard immunotherapy (pembrolizumab) works better than the standard drug alone for people with advanced head and neck cancer that has spread or come back. About 410 adults whose tumors have a specific marker …

This early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors (like lung, bladder, or breast cancer). The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be…

This study tests whether giving immune-boosting drugs before surgery can help shrink head and neck cancer tumors. About 80 adults with advanced but removable cancer will receive either nivolumab alone or combined with relatlimab or ipilimumab. Researchers will monitor side effect…